BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use
BeiGene’s Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a first-line combination treatment for adults with advanced gastric or oesophageal cancer. The drug has been authorised for use alongside platinum- and …